Research ArticleClinical Investigations
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy
Isabel Rauscher, Tobias Maurer, Ambros J. Beer, Frank-Philipp Graner, Bernhard Haller, Gregor Weirich, Alan Doherty, Jürgen E. Gschwend, Markus Schwaiger and Matthias Eiber
Journal of Nuclear Medicine November 2016, 57 (11) 1713-1719; DOI: https://doi.org/10.2967/jnumed.116.173492
Isabel Rauscher
1Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Tobias Maurer
2Department of Urology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Ambros J. Beer
3Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany
Frank-Philipp Graner
1Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Bernhard Haller
4Institute of Medical Statistics and Epidemiology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Gregor Weirich
5Department of Pathology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; and
Alan Doherty
6Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom
Jürgen E. Gschwend
2Department of Urology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Markus Schwaiger
1Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Matthias Eiber
1Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 11
November 1, 2016
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy
Isabel Rauscher, Tobias Maurer, Ambros J. Beer, Frank-Philipp Graner, Bernhard Haller, Gregor Weirich, Alan Doherty, Jürgen E. Gschwend, Markus Schwaiger, Matthias Eiber
Journal of Nuclear Medicine Nov 2016, 57 (11) 1713-1719; DOI: 10.2967/jnumed.116.173492
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy
Isabel Rauscher, Tobias Maurer, Ambros J. Beer, Frank-Philipp Graner, Bernhard Haller, Gregor Weirich, Alan Doherty, Jürgen E. Gschwend, Markus Schwaiger, Matthias Eiber
Journal of Nuclear Medicine Nov 2016, 57 (11) 1713-1719; DOI: 10.2967/jnumed.116.173492
Jump to section
Related Articles
Cited By...
- Validation of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment
- Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer
- 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
- Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard
- Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
- Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy
- Detection Rate of 18F-Choline PET/CT and 68Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes
- Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
- 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
- 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging
- Effects of Fasting on 18F-DCFPyL Uptake in Prostate Cancer Lesions and Tissues with Known High Physiologic Uptake
- Reply: Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
- Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
- 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
- PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice
- Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer
- Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
- Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment
- 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer
- 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution
- PSMA Ligands for PET Imaging of Prostate Cancer
- Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria
- The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer
- 68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy
- PET-Guided Stereotactic Irradiation of Prostate Cancer Lymph Node Metastases